RNXT Company Profile and Key Details

RNXT has shown mixed momentum, losing -0.95% over the past week and -7.14% over the past quarter, though year-to-date performance is up 23.79%. Short-term trend indicators are mixed aligned (SMA20 -9.59%, SMA50 -9.57%, SMA200 -21.9%). The stock’s 14-day RSI is 38.92 (weak momentum), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -40.34% below its high and over 23.47% above its low. Average 10-day trading volume of 1.46 million shares is significantly above the 3-month average of 446.03 thousand, indicating heightened recent market interest.

RenovoRx, Inc. has 45.13 million shares outstanding. The public float is 39.20 million shares, elevated short interest at 0.65% of float. This equals 283.44 thousand shares. The short ratio is 1.42 days. Institutional investors hold 21.1% of the float. Insiders own 3.42%. Agah Ramtin holds 798.46 thousand shares, VOLL MARK has 142.38 thousand shares and Spiegel Robert J. has 40.98 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

RenovoRx, Inc. (NASDAQ:RNXT) closed at $2.11 USD, gaining $0.18 (9.33%) from the previous close of $1.93. The stock is currently within 5% of its 52-week high $0.70 and $2.20. With a market capitalization of about $95.06 million, RenovoRx, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 402.01 thousand shares, trading with heavier-than-usual volume. Headquartered in Mountain View, CA, RenovoRx, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shaun R. Bagai, the company employs approximately 17 people and listed since August 26, 2021. RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies.

RenovoRx, Inc. generated EPS of -$0.36 over the past year. Five-year average earnings growth is 2.24%. Wall Street analysts project EPS growth of 51.14% annually over the next five years. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at -$0.08. Next year's EPS is expected at -$1.00. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $3.00. The high target offers 563.51% upside. The low target suggests 42.18% downside. The mean target is $11.20. This offers 430.81% upside. RenovoRx, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by -31.03%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 15, 2025.

RenovoRx, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that RenovoRx, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.06%, with price expected at $2.28 by September 15, 2026, within a range of $2.19 to $2.36 3-Month Outlook: Projected fall of -10.43%, reaching $1.89 by November 27, 2026, with a range of $1.83 to $1.97. 1-Year Outlook: Projected gain of 674.41%, with price at $16.34 by September 01, 2027, within a range of $4.91 to $19.92.

RenovoRx, Inc. (NASDAQ:RNXT) shares are up 23.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows RenovoRx, Inc. trading at a premium to the broader market with a P/E of -6.86. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.35, suggesting 343.13% upside. Our AI forecast model points to short-term strength (8.06% over two weeks), a medium-term fall (-10.43% over three months), and a longer-term gain (674.41% over one year), with expected trading ranges indicating moderate volatility.

RenovoRx, Inc. trades at a P/E ratio of -6.86, slightly below the S&P 500 average, with a price-to-sales ratio of 49.48 and a price-to-book ratio of 11.43 reflecting a rich premium to book value. The P/FCF stands at -8.19, also below market averages. Compared to sector medians, RenovoRx, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.